Abstract | INTRODUCTION: AREAS COVERED: EXPERT OPINION: The safety profiles of approved biologics, the TNF-α inhibitors etanercept and adalimumab, and the IL-6-inhibitor tocilizumab are highly acceptable. This conclusion is not easily expandable to the IL-1 inhibitor canakinumab as well as the T-cell-activation-inhibitor abatacept due to lack of experience; however, both have showed an excellent safety profile so far. An increase in knowledge about risk profiles in national and international collaborations, with national as well as international registries, is necessary.
|
Authors | Gerd Horneff |
Journal | Expert opinion on drug safety
(Expert Opin Drug Saf)
Vol. 14
Issue 7
Pg. 1111-26
(Jul 2015)
ISSN: 1744-764X [Electronic] England |
PMID | 26084637
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents
- canakinumab
- Adalimumab
- tocilizumab
- Etanercept
|
Topics |
- Adalimumab
(pharmacology)
- Antibodies, Monoclonal
(pharmacology)
- Antibodies, Monoclonal, Humanized
(pharmacology)
- Antirheumatic Agents
(pharmacology)
- Arthritis, Juvenile
(drug therapy)
- Biological Therapy
(methods)
- Child
- Clinical Trials as Topic
- Drug-Related Side Effects and Adverse Reactions
(classification, etiology)
- Etanercept
(pharmacology)
- Humans
- Product Surveillance, Postmarketing
(statistics & numerical data)
- Treatment Outcome
|